Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$81.00K$81.00Kderived+179.3% vs Q4 2020 Net Income-$2.95M-$2.95MderivedN/M vs Q4 2020 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$27,000+68.8% Operating Incomederived-$2,791,000N/M Operating Cash Flowderived-$2,505,000N/M Free Cash Flowderived-$2,594,000N/M Margins · derivedGross margin33.3%−21.8 pt vs Q4 2020
Operating margin-3445.7%+4978.5 pt vs Q4 2020
Net margin-3640.7%+7235.1 pt vs Q4 2020
ended Mar 31, 2021 · filed Jun 14, 2021 · 75 d after period end